Rinvoq vs Xeljanz
Upadacitinib vs Tofacitinib · Comparison Guide
Quick Comparison
| Feature | Rinvoq | Xeljanz |
|---|---|---|
| Generic Name | Upadacitinib | Tofacitinib |
| Manufacturer | AbbVie | Pfizer |
| Drug Class | JAK1 Inhibitor | JAK Inhibitor |
| Shared Conditions | Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis | |
Key Differences: Rinvoq vs Xeljanz
Both are JAK inhibitors taken orally but differ in selectivity: Rinvoq preferentially inhibits JAK1; Xeljanz inhibits JAK1 and JAK3. Post-marketing safety data for Xeljanz raised concerns about thrombosis, malignancy, and MACE leading to new black box warnings. Both are now limited in patients 50+ with cardiovascular risk factors. Rinvoq is FDA-approved for more indications (including Crohn's and atopic dermatitis). Prescribers may prefer Rinvoq's selectivity profile.
💊 Rinvoq (Upadacitinib)
- Class: JAK1 Inhibitor
- Manufacturer: AbbVie
- Full Rinvoq information →
💊 Xeljanz (Tofacitinib)
- Class: JAK Inhibitor
- Manufacturer: Pfizer
- Full Xeljanz information →
Both are JAK inhibitors taken orally but differ in selectivity: Rinvoq preferentially inhibits JAK1; Xeljanz inhibits JAK1 and JAK3. Post-marketing safety data for Xeljanz raised concerns about thrombosis, malignancy, and MACE leading to new black box warnings. Both are now limited in patients 50+ with cardiovascular risk factors. Rinvoq is FDA-approved for more indications (including Crohn's and atopic dermatitis). Prescribers may prefer Rinvoq's selectivity profile.
Neither Rinvoq nor Xeljanz is universally better — the right choice depends on your specific condition, disease severity, insurance formulary, and health history. Your prescriber will determine which is most appropriate based on your clinical situation. BiologicHealthPlus carries both and can help you compare your coverage and costs for either medication.
Switching between biologics is common. Your prescriber will evaluate your current treatment response and determine if a switch is appropriate. BiologicHealthPlus can coordinate the transition including prior authorization for your new medication.
Both Rinvoq and Xeljanz are covered by most commercial insurance plans, Medicare Part D, and Medicaid with prior authorization. BiologicHealthPlus handles insurance verification and prior authorization for both medications at no charge. Most insured patients pay $0–$35/month through manufacturer copay programs.
Rinvoq and Xeljanz both have high cash list prices ($4,000–$9,000/month range) but most commercially insured patients pay $0–$35/month through manufacturer savings programs. BiologicHealthPlus automatically enrolls every patient in all available savings programs at no charge.
✅ BiologicHealthPlus Carries Both Rinvoq and Xeljanz
We handle insurance verification, prior authorization, copay enrollment, and free cold-chain delivery for both medications. Contact us and we'll help you understand your options and costs.
Medical Disclaimer: This comparison is for educational purposes only. The choice between Rinvoq and Xeljanz should be made by your healthcare provider based on your specific medical history, disease severity, and individual circumstances. Last updated: July 2026.